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Abstract: Background: Cysteinyl leukotrienes (CysLTs) play a crucial role in the pathogenesis of
airway remodeling. The use of CysLTs receptor antagonists has been included in the management
of asthma and rhinitis. However, despite the action of these compounds on leukotriene production
has been well documented, their role in airway remodeling remains unclear. Objective: We aimed to
investigate the capability of the leukotriene receptor antagonist Montelukast to inhibit MMPs release
after CysLTs stimulation in nasal tissue fibroblasts. Methods: Fibroblasts were isolated from sinunasal
tissue collected from five patients suffering of chronic rhinosinusitis without nasal polyposis. Cells
were cultured and stimulated first with LTC4 and LTD4 (10´10, 10´8, 10´6 M) using as pre-stimulus
10 ng/mL of: IL-4, IL-13, or TGF-beta1 and in presence or absence of Montelukast (10´10, 10´8,
10´6 M). To evaluate the regulation of MMP-1 and TIMP-1 we used enzyme immunoassays and to
evaluate CysLT1 receptor we used real time PCR. Results: LTD4 but not LTC4 induced production
of mRNA for CysLT1 receptor in a dose dependent manner and with an additive effect when the
cells where primed with TGF-β1. TNF-α, IL-4, and IL-13 did not influence the expression of the
receptor. Levels of MMP-1 but not of TIMP-1 were statistically enhanced in cells primed with
TGF-β1 and stimulated with LTD4. Montelukast significantly decreased Cys-LT1 receptor and MMP-1
concentrations in a dose-dependent way in cells stimulated with LTD4 and TGF-β1 separately and
when they were applied together. Conclusion: The leukotriene pathway may play an important
role in extra-cellular matrix formation in an inflamed environment, such as chronic sinusitis and,
consequently, leukotriene receptor antagonists such as Montelukast may be of great benefit in
management of this disease.
Keywords: chronic rhinosinusitis; cysteinyl leukotriene receptor 1; fibroblasts; metalloproteinase 1;
Montelukast
1. Introduction
Chronic rhinosinusitis (CRS) is a heterogeneous group of diseases characterized by chronic
inflammation of the nasal and sinunasal mucosa, persisting longer than 12 weeks. Recent studies have
demonstrated that the spectrum of the disease can be differentiated into distinct subgroups based on
clinical parameters and on the characterization of the inflammatory response [1]. Although chronic
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rhinosinusitis without nasal polyps (CRSsNP) shows mainly a neutrophilic, TH1-driven inflammatory
profile, chronic rhinosinusitis with nasal polyps (CRSwNP) is mainly characterized by a TH2-skewed,
eosinophilic inflammation [1]. However, in both CRS phenotypes, the turnover of the extracellular
matrix (ECM) is disturbed by the release of inflammatory mediators such as TGF-β1, MMP-7, MMP-9,
and TIMP-1 in nasal secretions. Resulting in an abnormal tissue remodeling characterized by mucosal
thickening, fibrosis, and/or edema [2,3].
ECM remodeling processes consist of a complex interaction between various cell types and a
large number of enzymes including tissue serine proteases and the family of matrix metalloproteinases
(MMPs) [4]. Matrix metalloproteinases (MMPs) are a family of zinc- and calcium-dependent
endopeptidases which can collectively degrade almost all ECM components [5]. They are produced
by structural (fibroblasts, endothelial, and epithelial cells) and inflammatory cells (eosinophils,
macrophages, neutrophils, and lymphocytes) and the gene expression is tightly regulated by cytokines
and growth factors.
The role of MMPs in physiology has been implicated in both normal and pathological structural
processes, such as embryogenesis, cell migration, tissue repair, and tumor necrosis [6,7]. The increased
expression of MMPs in nasal polyps, COPD, and asthma and the correlation with pathological
changes of the airways, together with their action in wound repair have been the basis to suggest the
possible role of these compounds in microvascular permeability, cell transmigration, and ECM airway
remodeling [8]. Although this evidence exists, the in vivo function of these MMPs in airway diseases
remains partially unclear.
Cysteinyl leukotrienes (CysLTs) are lipid mediators produced after the release of arachidonic acid
from cell membrane phospholipids which is then modified by the 5-lipoxygenase (ALOX5) enzyme to
yield LTB4 or to the cysteinyl-leukotrienes (CysLTs) LTC4, LTD4, and LTE4 [9]. These compounds are
released by cells involved in the inflammatory response (mast cells, basophils, eosinophils, neutrophils,
and macrophages) and constitute important pro-inflammatory mediators in asthma and other chronic
inflammatory diseases [9,10]. Their action is mediated by the binding to CysLTs receptors (CysLT1
and CysLT2 receptors), which are expressed not only in inflammatory and immune cells, but also in
structural cells. Binding of CysLTs on their receptors on structural cells results in tissue edema, mucus
secretion, bronchoconstriction, and severe impairment in tissue remodeling [11].
In nasal tissue of CRSsNP patients, levels of the CysLTs, the enzymes involved in their synthesis
(ALOX5 and LTC4S), and both CysLT1 and CysLT2 receptors are significantly upregulated compared
to controls [12,13]. Several in vitro experiments have suggested that CysLTs may induce airway smooth
muscle proliferation [14,15], alter fibroblast function [16,17] and induce extracellular matrix [18,19].
Taking into account the important role of leukotrienes in airway inflammation, and especially in
asthma, several anti-LTs modifiers have been evaluated in the management of this pathology [20–22].
Leukotriene modifiers include three different groups of drugs: (i) specific inhibitors of FLAP;
(ii) inhibitors of ALOX5; and (iii) CysLT1 receptor inhibitors. However, the role of these compounds in
upper airway remodeling remains unclear. In this study we evaluated the capability of exogenous
CysLTs (LTC4 and LTD4) to influence the expression of MMPs in nasal tissue fibroblasts isolated from
patients with chronic rhinosinusitis without nasal polyposis (CRSsNP) and evaluate if the leukotriene
receptor antagonist Montelukast may modify this effect and, consequently, may have a potential role
in regulation upper airway tissue remodeling.
2. Materials and Methods
2.1. Patients
Fibroblasts were isolated from nasal mucosa tissue obtained from CRSsNP patients (n = 5) who
were scheduled for functional endoscopic sinus surgery at the Department of Otorhinolaryngology
at Ghent University Hospital. The diagnosis of CRSsNP was based on history, clinical examination,
nasal endoscopy, and computed tomography (CT-Scan) of the paranasal cavities according to the EPOS
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guidelines [23]. None of the patients had asthma or allergies as assessed by the guidelines (GINA) for
the diagnosis and management of asthma [24] and results of a skin prick test. The study was approved
by the ethical committee of Ghent University Hospital and all patients gave informed consent before
their participation.
2.2. Reagents
Dulbecco’s PBS, penicillin-streptomycin (penicillin, 5000 IU/mL; streptomycin, 50 µg/mL),
and trypan blue (0.4% solution in PBS) were obtained from Invitrogen (Paisley, UK). Minimum
essential medium (MEM), Opti-MEM I reduced serum medium, L-glutamine (200 mM), trypsin-EDTA
(1X), and fetal bovine serum (FBS) (qualified; origin, Thermo Fisher Scientific, Waltham, MA, USA)
were purchased from Gibco (Life Technologies, Carlsbad, CA, USA). Ultroser™ G serum substitute
(5%) was obtained from BioSepra (Port Washington, New York, NY, USA). Interleukin-4 (IL-4) and
interleukin—13 (IL-13) were obtained from R and D Systems (Minneapolis, MN, USA). SYBR Green I
qPCR Master mix, Aurum Total RNA, and Script cDNA synthesis kits were obtained from Bio-Rad
Laboratories (Berkeley, CA, USA). Cysteinyl leukotrienes C4, -D4 (LTC4, LTD4) and the cysteinyl
leukotriene receptor 1 (CysLT1) inhibitor Montelukast were purchased from Cayman Chemicals
(Ann Arbor, MI, USA).
2.3. Isolation of Nasal Mucosa Fibroblasts
Nasal sinus tissues, obtained from patients with chronic rhinosinusitis, during surgical
operations were rinsed several times with Opti-MEM I supplemented with 5% FBS, 5% Ultroser
G, 2 mmol/L glutamine, and penicillin (50 IU/mL)–streptomycin (50 µg/mL), and cut into small
pieces (approximately 1 mm2). Diced specimens were then plated (density, 9 pieces/6-well tissue
culture dish) and incubated in a humidified atmosphere containing 5% CO2 at 37 ˝C, until a monolayer
of fibroblast-like cells was observed to be confluent. Then, the explanted tissues were removed,
and cells were trypsinized and re-plated into 250-cm2 tissue culture Falcon tubes at a final volume of
5 mL. The culture medium was then changed every three days for 2–3 weeks until 90% confluence was
obtained. Subsequently, the cells were split and stained with antibodies against vimentine, cytokeratin,
and α-smooth muscle actin to exclude contamination with epithelial cells.
2.4. Cell Stimulation
Cells (1 ˆ 106) were cultured with 10 ng/mL of IL-4, IL-13, TGF-β1, and TNF-α alone or in
combination with (10´6, 10´8 and 10´10 M) of LTC4 or LTD4 independently during 24 h at 37 ˝C
in 5% CO2. For inhibition experiments, sinunasal fibroblasts where first cultured in presence of
Montelukast (10´8, 10´10, 10´11 M) for 60 min, and after, stimulated with 10 ng/mL of TGF-β1 or in
combination with LTD4 at 10´6 M) for 24 h, at 37 ˝C in 5% CO2. After all stimulations, supernatants
were collected and stored at ´20 ˝C until use. Cells were resuspended in lysis buffer for posterior
RNA extraction, and stored at ´80 ˝C.
2.5. Measurement of MMP-1, TIMP-1, and Cysteinyl Leukotrienes
Protein levels of matrix metalloproteinase-1, -2, -3, -7, and -9 (MMP-1, MMP-2, MMP-3, MMP-7,
and MMP-9) and TIMP-1 were quantified by the human total MMPs and TIMP-1 Quantikine ELISA
kits (R and D Systems) following manufacturer’s instructions.
2.6. Real-Time qPCR for CYSLT1 Receptor
Cell pellet was homogenized in Tri-reagent buffer (Sigma-Aldrich, MO, USA), 1 mL per 50–100 mg
of tissue and total RNA was isolated using the Aurum total RNA Kit (BioRad Inc. Laboratories)
following the manufacturer’s instructions. cDNA was synthesized from 2 µg of total RNA using the
iScript cDNA synthesis kit Bio-Rad Inc. Laboratories). Amplification reactions were performed on an
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iQ5 Real-Time PCR Detection System (Bio-Rad Laboratories) using a primer set for human cysteinyl
leukotriene receptor 1 (Table 1). PCR reactions contained 20 ng of cDNA (total RNA equivalent)
of unknown samples, 1X SYBR Green I Master mix (Bio-Rad Laboratories) and 250 nM of primer
pairs in a final volume of 20 µL. PCR protocol consisted of one cycle at 95 ˝C for 10 min followed by
40 cycles at 95 ˝C for 15 s and at 60 ˝C for 1 min. The expression of two housekeeping genes, Beta
actin (ACTB) and hydroxymethyl-bilane synthase (HMBS), were used to normalize for transcription
and amplification variations among samples. Primer sequences and qPCR conditions are reported
previously [25]. Relative normalized quantities were calculated from the obtained Cq values using the
qBase software [26].
Table 1. Primer sequence for quantitative real-time PCR.
Gene Forward Primer 51Ñ 31 Reverse Primer 51Ñ 31 AmpliconSize (bp)
GenBank
Accession
Number
CysLT1 TCCTTAGAATGCAGAAGTCCGTG AAATATAGGAGAGGGTCAAAGCAA 80 NM_001282187
ACTB CTGGAACGGTGAAGGTGACA AAGGGACTTCCTGTAACAATGCA 139 NM_001101.3
HMBS GGCAATGCGGCTGCAA GGGTACCCACGCGAATCAC 154 NM_000190.3
2.7. Statistical Analysis
The data generated in this study was analyzed using the MedCalc software version 6.0
(Mariakerke, Belgium). To demonstrate statistical differences between the different stimulation
conditions we used the Wilcoxon test for paired samples, which is a non-parametric alternative
method for the paired-samples t-test when the distribution of the samples is not normal, p values equal
or less than 0.05 was regarded as significant.
3. Results
3.1. Effect of LTC4, LTD4, and Cytokines on the Expression of CysLT1 Receptor
Nasal tissue fibroblasts from chronic rhinosinusitis patients were able to express CysLT1 receptor
mRNA levels but at very low levels. Stimulation with LTC4 did not influence the gene expression of
the receptor when compared to non-stimulated cells; in contrast to LTD4 that upregulated the mRNA
levels of the receptor in a dose-dependent manner being 10´8 M the concentration with the highest
effect (Figure 1).
Based on that fribroblasts may change their behaviour and activation profiles when they are
under influence of certain cytokine millieu, we decided to study the effect of IL-4, IL-13, TNF-α and
TGF-β1 on the expression of CysLT1 receptor. Results of this stimulation showed that IL-4, IL-13, and
TNF-α had no influence on the gene expression of CysLT1 receptor. In contrast, TGF-β1 significantly
increased the expression of the receptor when compared to unstimulated cells (Figure 2).
To evaluate the effect of cytokines on the changes induced by LTD4 on CySLT1 receptor expression,
chronic rhinosinusitis fibroblasts were pre-incubated 24 h with 10 ng/mL of TGF-β1 and, subsequently,
with different concentrations of LTD4. Of interest, an additive effect on the regulation of CysLT1
receptor was observed. This effect was more pronounced at the LTD4 concentration of 10´8 M as
shown in Figure 3.
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Figure 1. Messenger RNA expression levels of CysLT1 receptor in fibroblasts from chronic 
rhinosinusitis tissue after stimulation with cysteinyl leukotriene C4 (LTC4) and D4 (LTD4). NRQU: 
normalized relative quantification units; p value represents the level of significance after a Wilcoxon 
test for paired samples. 
 
Figure 2. Messenger RNA expression levels of CysLT1 receptor in fibroblasts from chronic 
rhinosinusitis tissue after stimulation with Interleukin-4 (IL-4), interleukin-13 (IL-13), TNF-α, and 
TGF-β1. NRQU: normalized relative quantification units; p value represent the level of significance 
after a Wilcoxon test for paired samples. 
Figure 1. Messenger RNA expression levels of CysLT1 receptor in fibroblasts from chronic rhinosinusitis
tissue after stimulation with cysteinyl leukotriene C4 (LTC4) and D4 (LTD4). NRQU: normalized relative
quantification units; p value represents the level of significance after a Wilcoxon test for paired samples.
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Figure 2. Messenger RNA expression levels of CysLT1 receptor in fibroblasts from chronic rhinosinusitis
tissue after stimulation with Interleukin-4 (IL-4), interleukin-13 (IL-13), TNF-α, and TGF-β1. NRQU:
normalized relative quantification units; p value represent the level of significance after a Wilcoxon test
for paired samples.
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Figure 3. Messenger RNA expression levels of CysLT1 receptor in fibroblasts from chronic rhinosinusitis 
tissue after stimulation with TGF-β1 and LTD4. NRQU: normalized relative quantification units;  
p value represents the level of significance after a Wilcoxon test for paired samples. 
3.2. Effect of LTC4, LTD4, and Cytokines on the Release of Metalloproteinases 
Protein levels of MMP-2, MMP-3, MMP-7, and MMP-9 were below detection limit in all experimental 
conditions. Only MMP-1 and TIMP-1 were released during basal conditions. Further, LTD4 increased 
the levels of MMP-1 in a dose-dependent way being the concentration of 10−8 M the one showing the 
best effect (Figure 4). No changes were observed in the expression of TIMP-1 by the addition of LTC4 
or LTD4 in the culture medium. 
 
Figure 4. Concentrations of metalloproteinase 1 (MMP-1) and tissue inhibitor of metalloproteinase 1 
(TIMP-1) in fibroblasts from chronic rhinosinusitis tissue after stimulation with LTD4. p value 
represents the level of significance after a Wilcoxon test for paired samples. 
Figure 3. Messenger RNA expression levels of CysLT1 receptor in fibroblasts from chronic rhinosinusitis
tissue after stimulation with TGF-β1 and LTD4. NRQU: normalized relative quantification units; p value
represents the level of significance after a Wilcoxon test for paired samples.
3.2. Effect of LTC4, LTD4, and Cytokines on the Release of Metalloproteinases
Protein levels of MMP-2, MMP-3, MMP-7, and MMP-9 were below detection limit in all
experimental conditions. Only MMP-1 and TIMP-1 were released during basal conditions. Further,
LTD4 increased the levels of MMP-1 in a dose-dependent way being the concentration of 10´8 M the
one showing the best effect (Figure 4). No changes were observed in the expression of TIMP-1 by the
addition of LTC4 or LTD4 in the culture medium.
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Figure 4. Concentrations of metalloproteinase 1 (MMP-1) and tissue inhibitor of metalloproteinase 1 
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Figure 4. Concentrations of metalloproteinase 1 (MMP-1) and tissue inhibitor of metalloproteinase 1
(TIMP-1) in fibroblasts from chronic rhinosinusitis tissue after stimulation with LTD4. p value represents
the level of significance after a Wilcoxon test for paired samples.
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Pre- incubation of the cells with IL-4, IL-13, TGF-β1, TNF-α alone or in combination with LTD4
failed to induce changes in TIMP-1 production. Expression of MMP-1 was, however, significantly
induced after TGF-β1 and TNF-α stimulation alone and in combination with 10´8 M of LTD4 when
compared to non-timulated cells (Figure 5). Addition of TNF-α increased the concentrations of MMP1
but this effect was not related to cytokine concentration, and a non-additive effect was observed
after addition of LTD4. The upregulation of MMP-1 levels by TGF-β1 was more potent than the one
observed with LTD4 alone. An additive dose-dependent effect on MMP-1 production was obtained
when combined with the two compounds in the culture (Figure 5).
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Figure 5. Concentrations of metalloproteinase 1 (MMP-1) in fibroblasts from chronic rhinosinusitis 
tissue after stimulation with LTD4 and TGF-β1. p value represents the level of significance after a 
Wilcoxon test for paired samples. 
3.3. Effect of Montelukast on MMP-1 and CysLT1 Receptor Expression Induced by LTD4 and TGF-β1 
Montelukast inhibited the CysLT1 receptor mRNA expression in a dose-dependent manner in 
fibroblasts stimulated with LTD4, but also attenuated the increase in receptor expression induced by 
TGF-β1 alone and in combination with LTD4 (Figure 6). The leukotriene receptor antagonist also 
restablished in a dose-dependant way the concenrations of MMP1 to baseline levels in fibroblasts 
stimulated with TGF-β1 and with LTD4 alone or in combination. However, the lowest concentrations 
of Montelukast did not diminish the expression of MMP-1 to baseline levels in the cells pre-
stimulated with TGF-β1 (Figure 7). 
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3.3. Effect of ontelukast on P-1 and CysLT1 Receptor Expression Induced by LT 4 and TGF-β1
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by TGF-β1 alone and in combination with LTD4 (Figure 6). The leukotriene receptor antagonist also
restablished in a dose-dependant ay the concenrations of P1 to baseline levels in fibroblasts
sti ulated ith TGF-β1 and ith LTD4 alone or in co bination. o ever, the lo est concentrations
of ontelukast did not diminish the expression of MMP-1 to baseline levels in the cells pre-stimulated
with TGF-β1 (Figure 7).
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Figure 6. mRNA expression of CYSLT1 receptor in fibroblasts from chronic rhinosinusitis tissue after 
stimulation with LTD4 and TGF-β1 and in presence or absence of Montelukast. NRQU: normalized 
relative quantification units, *: p value < 0.05 when compared to tissue culture medium (Opti-MEM), 
§: p value < 0.05 when compared to LTD4 (10−8 M), $: p value < 0.05 when compared to TGF-β1, #: p 
value < 0.05 when compared to TGF-β1 + LTD4. Tukey’s multiple comparisons test for CysLT1 receptor 
expression in Supplementary Table S1. 
 
Figure 7. Concentrations of metalloproteinase 1 (MMP-1) in fibroblasts from chronic rhinosinusitis 
tissue after stimulation with LTD4 and TGF-β1 and in presence or absence of Montelukast. *: p value 
< 0.05 when compared to tissue culture medium (Opti-MEM), §: p value < 0.05 when compared to LTD4 
(10−8 M), $: p value < 0.05 when compared to TGF-β1, #: p value < 0.05 when compared to TGF-β1 + LTD4. 
Tukey’s multiple comparisons test for MMP1 protein concentrations Supplementary Table S2. 
Figure 6. mRNA expression of CYSLT1 receptor in fibroblasts from chronic rhinosinusitis tissue after
stimulation with LTD4 and TGF-β1 and in presence or absence of Montelukast. NRQU: normalized
relative quantification units, *: p v lue < 0.05 when compared to tissue culture medium (Opti-MEM),
§: p value < 0.05 when compared to LTD4 (10´8 M), $: p value < 0.05 when compared to TGF-β1,
#: p value < 0.05 when compared to TGF-β1 + LTD4. Tukey’s multiple comparisons test for CysLT1
receptor expression in Supplementary Table S1.
Sinusitis 2016, 1, 65–75 72 
 
 
Figur  6. mRNA express on of CYSLT1 receptor in fibroblasts from chronic hinosinusitis tissue after 
stimul tion with LTD4 and TGF-β1 and in pres ce r absence of Montelukast. NRQU: normalized 
relative quantification units, *: p value < 0.05 when co pared to tissue cultur  medium (Opti-MEM), 
§: p value < 0.05 when compared to LTD4 (10−8 M), $: p value < 0.05 when compared to TGF-β1, #: p 
value < 0.05 when compared to TGF-β1 + LTD4. Tukey’s multiple comparisons test for CysLT1 receptor 
expression in Supplementary Table S1. 
 
Figure 7. Concent ations of metalloproteinase 1 (M P-1) in fibroblasts from chronic rhinosinusitis 
tissue after stimulation ith LTD4 and TGF-β1 and in pres nce or abs e of Montelukast. *: p value 
< 0.05 when compared to tissue cultu e medium (Opti-MEM), §: p value < 0.05 when compared to LTD4 
(10−8 M), $: p value < 0.05 when compared to TGF-β1, #: p value < 0.05 when compared to TGF-β1 + LTD4. 
Tukey’s multiple comparisons test for MMP1 protein concentrations Supplementary Table S2. 
Figure 7. Concentrations of metalloprot inase (MMP-1) in fibroblasts from chronic rhinosinusitis
tissue after stimulati n with LTD4 and TGF-β1 and in presence or absence f Montelukast.
*: p value < 0.05 when compared to tissue culture medium (Opti-MEM), §: p value < 0.05 when
compared to LTD4 (10´8 M), $: p value < 0.05 when compared to TGF-β1, #: p value < 0.05 when
compared to TGF-β1 + LTD4. Tukey’s multiple comparisons test for MMP1 protein concentrations
Supplementary Table S2.
4. Discussion
The main finding of this study is that TGF-β1 and LTD4 are potent inducers of MMP-1 protein
in chronic rhinosinusitis tissue-derived fibroblasts and that this effect is mediated, in part, by the
CysLT1 receptor and, hence, could be attenuated by its antagonist Montelukast. The effect of TGF-β1
on MMP-1 production have been reported in lower airways; however, this is the first report in nasal
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tissue fibroblasts. In CRSsNP tissue, MMP-1 levels are increased when compared to healthy nasal
mucosa and it is mainly localized in the nasal epithelium and mucosal and sub-mucosal glands, as
well as in some infiltrated inflammatory cells [27]. Further, TGF-β1 and CysLTs are also increased
in CRSsNP tissue when compared to non-inflamed nasal mucosa, as reported by Van Bruaene and
Perez Novo et al., respectively [12,28]. Balance in collagen degradation MMPs is a crucial mechanism
leading to an appropriate tissue wound healing process where fibroblasts represent one of the major
cells involved [2].
Leukotrienes play an important role in the regulation of MMP synthesis and, hence, in the
remodeling process by enhancing collagenase mRNA expression [29]. Medina et al. demonstrated
that LTD4 and IL-1β could induce the secretion of MMP-1 in airway smooth muscle cells resulting
in the stimulation of cell proliferation [30]. More recently, it has been suggested that LTD4 has the
potential to augment fibroblast chemotaxis, and to contribute to the regulation of the wound healing
and remodeling in fibrotic processes of the lung [31,32]. LTD4 may also increase collagen production
in activated myofibroblasts by upregulating CysLT1 receptor induced by TGF-β1 [33]. This evidence
strongly supports the possible role of lipid mediators, and especially cysteinyl leukotrienes, in airway
remodeling and in the regulation of MMP production.
The action of TGF-β1 through the CysLT1 receptor in the regulation of ECM molecules has
been previously reported by Asakura et al. [33]. However, in that study LTD4 in combination with
TGF-β1 stimulated the production of collagen in a human fetal lung fibroblasts cell line. Our results
showed that the same compounds also induced the production of MMP-1, which can induce collagen
degradation. This discrepancy can be due to the differences in cell type (lung derived cell line versus
primary nasal tissue cells). As stated before MMP-1 degrades collagen. In a previous work we observed
that collagen content in CRSsNP is higher than in control and CRSwNP tissues [28]. This is perfectly
possible if we take into account that fibroblasts are not the only cells producing MMPs, and in our
study we exclude the contribution of these cells. Further the expression of collagen and the influence
of other cytokines, which are present in physiological conditions, could not be tested in this study.
It is important to mention that in the study of Steinke et al., [34] the authors failed to show
CyLT1 receptor expression in nasal polyp fibroblasts. One explanation for this discrepancy could be
the high levels of TGF-β1 present in CRSsNP tissue; this growth factor is an important inducer of
CyLT1 receptor as demonstrated by several research works and observed in our study. This factor
is also important in the transformation of fibroblasts into myofibroblasts. Fibroblasts isolated from
CRSsNP could retain these properties during the seeding procedure and it may be the cause of the low
expression of CyLT1 receptor observed. Furthermore, it has been documented from several authors
that fibroblast behavior between CRS with and without polyps, and even between polyp subtypes,
(for example, with and without asthma or aspirin-exacerbated disease) is different.
To conclude, we can state that the release of cytokines like TGF-β1 and lipid mediators like CysLTs
by inflammatory cells can significantly contribute to the regulation of fibroblast CysLT1 receptor and
MMP-1 pathways. This is of relevance due to high levels of these molecules observed in chronic
rhinosinusitis tissue. Montelukast is a potent and specific CysLT1 receptor inhibitor that has been
shown to cause a significant decrease in sputum and peripheral blood eosinophil number, reduce
concentrations of eosinophilic cationic protein, of LTC4 and exhaled nitric oxide levels in asthmatic
patients [35,36]. However, despite the action of leukotriene modifiers, it has been well documented
that its role in upper airways remodeling remains unclear. The findings obtained in this study are in
line with previous in vitro and animal studies, suggesting the use of Montelukast as a modifier of lower
airway remodeling. Our work involved human nasal fibroblasts from chronic rhinosinusitis patients
adding more evidence for the potential role of this LTR antagonist in regulating the remodeling process
in upper airways.
Supplementary Materials: The following are available online at http://www.mdpi.com/2309-107X/1/1/65/s1,
Table S1: Tukey’s multiple comparisons test for CysLT1 receptor expression. Table S2: Tukey’s multiple
comparisons test for MMP1 protein concentrations.
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